Tuesday, Aug 16, 2022
English News
  • Hyderabad
  • Telangana
  • Andhra Pradesh
  • India
  • World
  • Entertainment
  • Science and Tech
  • Sport
  • Business
  • ...
    • NRI
    • View Point
    • cartoon
    • Columns
    • Reviews
    • Education Today
    • Property
    • Videos
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • Columns
  • Reviews
  • Education Today
  • Property
  • Videos
  • Lifestyle
Home | World | Novavax Large Study Finds Covid 19 Shot About 90pc Effective

Novavax: Large study finds Covid-19 shot about 90pc effective

By AP
Published: Published Date - 04:08 PM, Mon - 14 June 21
Novavax: Large study finds Covid-19 shot about 90pc effective
Representational Image. The Novavax vaccine, which is easy to store and transport, is expected to play an important role in boosting vaccine supplies in the developing world.

Washington: Vaccine maker Novavax said Monday its shot was highly effective against COVID-19 and also protected against variants in a large, late-stage study in the US and Mexico.

The vaccine was about 90 per cent effective overall and preliminary data showed it was safe, the company said.

While demand for COVID-19 shots in the US has dropped off dramatically, the need for more vaccines around the world remains critical. The Novavax vaccine, which is easy to store and transport, is expected to play an important role in boosting vaccine supplies in the developing world.

That help is still months away, however. The company says it plans to seek authorization for the shots in the US, Europe and elsewhere by the end of September and be able to produce up to 100 million doses a month by then.

“Many of our first doses will go to … low- and middle-income countries, and that was the goal to begin with,” Novavax Chief Executive Stanley Erck told The Associated Press.

While more than half of the US population has had at least one COVID-19 vaccine dose, less than 1 percent of people in the developing world have had one shot, according to Our World In Data.

Novavax’s study involved nearly 30,000 people ages 18 and up in the US and Mexico. Two-thirds received two doses of the vaccine, three weeks apart, and the rest got dummy shots.

There were 77 cases of COVID-19 — 14 in the group that got the vaccine and the rest were in volunteers who received dummy shots. None in the vaccine group had moderate or severe disease, compared to 14 in the placebo group.

The vaccine was similarly effective against several variants including the one first detected in the U.K. that’s dominant in the US, and in high-risk populations including the elderly and people with other health problems.

Side effects were mostly mild — tenderness and pain at the injection site. There were no reports of unusual blood clots or heart problems, Erck said.

Novavax reported the results in a press release and plans to publish in a medical journal, where it will be vetted by independent experts. The Maryland-based company previously released findings from smaller studies in Britain and South Africa.

COVID-19 vaccines train the body to recognize the coronavirus, especially the spike protein that coats it, and get ready to fight the virus off. The Novavax vaccine is made with lab-grown copies of that protein. That’s different from some of the other vaccines now widely used, which include genetic instructions for the body to make its own spike protein.

The Novavax vaccine can be stored in standard refrigerators, making it easier to distribute.
Novavax previously announced manufacturing delays due to supply shortages. The company now expects to reach production of 100 million doses a month by the end of September and 150 million doses a month by December.

The company has committed to supplying 110 million doses to the US over the next year and a total of 1.1 billion doses to developing countries.

In May, vaccines alliance Gavi announced it had signed an agreement to buy 350 million doses of Novavax’s vaccine, with deliveries estimated to begin in the third quarter. COVAX, the global initiative to provide vaccines to countries, is facing a critical shortage of vaccines after its biggest supplier in India suspended exports until the end of the year, Novavax has been working on developing vaccines for more than three decades, but hasn’t brought one to market.

The company’s coronavirus vaccine work is partly funded by the US government.


Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .

  • Follow Us :
  • Tags
  • Covid -19 shot
  • Novavax
  • Novavax Chief Executive Stanley Erck

Related News

  • WHO approves emergency use of Covovax

    WHO approves emergency use of Covovax

  • SII vaccine for 3+ kids by mid-2022: Adar Poonawalla

    SII vaccine for 3+ kids by mid-2022: Adar Poonawalla

  • SII begins manufacturing Covovax; to start trial in kids in July

    SII begins manufacturing Covovax; to start trial in kids in July

  • Novavax Covid vaccine effective against South African variant

    Novavax Covid vaccine effective against South African variant

  • Warangal CP urges cops to get Covid vaccine jab

    Warangal CP urges cops to get Covid vaccine jab

  • Novavax found 96% effective against Covid in phase 3 trial

    Novavax found 96% effective against Covid in phase 3 trial

Latest News

  • India logs 8,813 new Covid infections, active cases decline to 1,11,252

    20 mins ago
  • Karnataka: Two youth stabbed after Veer Savarkar’s flex removed in Shivamogga

    33 mins ago
  • Chinese research ship docks at Sri Lanka’s Hambantota port amid India’s concern

    47 mins ago
  • FIFA suspends All India Football Federation due to ‘undue influence’ from third parties

    1 hour ago
  • Cyber Talk: Women, stay safe online

    9 hours ago
  • Opinion: When problems are more profitable

    10 hours ago
  • JNTU-Hyderabad to start private college inspections from August 18

    10 hours ago
  • Editorial: Tread cautiously

    10 hours ago

company

  • Home
  • About Us
  • Contact Us

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

© Copyrights 2022 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam